Evaluation of R-Mix shell vials for the diagnosis of viral respiratory tract infections.
Respiratory viruses cause significant morbidity and mortality. The management of these infections can be improved by a rapid diagnosis and administration of available virus-specific therapy. The goal of this study was to compare R-Mix, an engineered tissue monolayer for rapid shell vial (SV) diagnosis of viral respiratory infections, with conventional tissue culture (TC) and conventional respiratory SV (primary rhesus monkey kidney (RhMK) and Hep2 monolayers). The primary outcome measure was sensitivity for detection of influenza A and B, respiratory syncytial virus, parainfluenza 1-3, and adenovirus. The study was performed in two phases: (1) the three methods were compared using 250 nasal washes from children with lower respiratory tract infections; (2) a modified R-Mix SV harvesting schedule (SV were harvested at 24 and 120 h) was compared with TC and conventional RhMK/Hep2 SV using 311 respiratory specimens. A total of 110 viruses were identified in the first and 55 in the second phase. Diagnostic accuracies of R-Mix harvested at 24, 48, and 120 h were 98%, whereas for TC varied between 99 and 100%, and for RhMK/Hep2 SV between 98 and 99%. Sensitivities of R-Mix harvested at 24, 48, and 120 h were 26, 75, and 47%, respectively, whereas for TC varied between 60 and 94%, and for RhMK/Hep2 SV between 62 and 85%. R-Mix harvested at 48 h represent a valuable substitute for RhMK/Hep2 SV because they have comparable sensitivities and diagnostic accuracies, but R-Mix offers several technical advantages. In contrast, R-Mix harvested at 24h did not seem a very useful diagnostic tool. The utility of R-Mix harvested at 120 h, which accelerated the diagnosis of 16% of positive specimens in study phase 2, needs further investigation.
Weinberg
Adriana
A
University of Colorado Health Sciences Center, Campus Box C227, 4200 E 9th Avenue, Denver, CO 80262, USA. adriana.weinberg@uchsc.edu
Brewster
Lori
L
Clark
Julia
J
Simoes
Eric
E
D000260:Adenoviruses, Human / Q000254:growth & development / Q000302:isolation & purification; D000818:Animals; D002460:Cell Line; D002648:Child; D006801:Humans; D009980:Influenza A virus / Q000254:growth & development / Q000302:isolation & purification; D009981:Influenza B virus / Q000254:growth & development / Q000302:isolation & purification; D017817:Nasal Lavage Fluid / Q000821:virology; D009975:Orthomyxoviridae / Q000254:growth & development / Q000302:isolation & purification*; D009976:Orthomyxoviridae Infections / Q000175:diagnosis* / Q000821:virology; D010222:Parainfluenza Virus 1, Human / Q000254:growth & development / Q000302:isolation & purification; D010223:Parainfluenza Virus 2, Human / Q000254:growth & development / Q000302:isolation & purification; D010224:Parainfluenza Virus 3, Human / Q000254:growth & development / Q000302:isolation & purification; D010252:Paramyxoviridae / Q000254:growth & development / Q000302:isolation & purification*; D018184:Paramyxoviridae Infections / Q000175:diagnosis* / Q000821:virology; D011237:Predictive Value of Tests; D018113:Respiratory Syncytial Virus, Human / Q000254:growth & development / Q000302:isolation & purification; D012141:Respiratory Tract Infections / Q000175:diagnosis* / Q000821:virology; D012680:Sensitivity and Specificity; D013997:Time Factors; D014776:Virus Cultivation